Kurt Van Baelen

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B3, 2800 Mechelen, Belgium
    Antimicrob Agents Chemother 53:2185-8. 2009
  2. ncbi A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Virol Methods 161:231-9. 2009
  3. ncbi Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B4, 2800Mechelen, Belgium
    AIDS 22:1877-80. 2008
  4. ncbi Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance
    Theresa Pattery
    Virco BVBA, Beerse, Belgium
    Intervirology 55:138-46. 2012
  5. ncbi HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B4, 2800 Mechelen, Belgium
    J Virol Methods 146:61-73. 2007
  6. ncbi A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay
    David Nauwelaers
    Virco BVBA, Beerse, Belgium
    PLoS ONE 6:e19643. 2011
  7. ncbi HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays
    Ina Vandenbroucke
    Tibotec Virco Virology BVBA, Mechelen, Belgium
    AIDS Res Ther 7:4. 2010

Collaborators

Detail Information

Publications7

  1. ncbi Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B3, 2800 Mechelen, Belgium
    Antimicrob Agents Chemother 53:2185-8. 2009
    ..We found that reduced BVM susceptibility was associated with naturally occurring polymorphisms at positions 6, 7, and 8 in Gag spacer peptide 1...
  2. ncbi A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B3, Mechelen, Belgium
    J Virol Methods 161:231-9. 2009
    ..1 and 2.0 for raltegravir and elvitegravir, respectively. In summary, a genotypic and phenotypic integrase resistance assay was validated successfully for accuracy, reproducibility, analytical and clinical sensitivity, and dynamic range...
  3. ncbi Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B4, 2800Mechelen, Belgium
    AIDS 22:1877-80. 2008
    ..91 +/- 0.40, and 0.84 +/- 0.37. Phenotypic testing proved that clade-specific integrase polymorphisms do not contribute to reduced susceptibility towards integrase inhibitors...
  4. ncbi Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance
    Theresa Pattery
    Virco BVBA, Beerse, Belgium
    Intervirology 55:138-46. 2012
    ..Resistance testing is currently recommended within the standard of care guidelines to aid the choice of new drug regimens following treatment failure(s)...
  5. ncbi HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays
    Kurt Van Baelen
    Virco BVBA, Generaal De Wittelaan L11 B4, 2800 Mechelen, Belgium
    J Virol Methods 146:61-73. 2007
    ..Finally, population NH(2)-V4 gp120 phenotypic tropism determination appeared to be a promising tool for the detection of minority species present in the amplified envelope fragments...
  6. ncbi A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay
    David Nauwelaers
    Virco BVBA, Beerse, Belgium
    PLoS ONE 6:e19643. 2011
    ....
  7. ncbi HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays
    Ina Vandenbroucke
    Tibotec Virco Virology BVBA, Mechelen, Belgium
    AIDS Res Ther 7:4. 2010
    ..While good concordance was observed between gp120 phenotyping and prediction of R5-tropic virus, the results suggest that accurate prediction of X4-tropic virus would require further algorithm development...